Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , May 31, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 31, 2019 , under Fluidigm’s
View HTML
Toggle Summary Fluidigm Introduces Advanta RNA Fusions NGS Library Prep Assay to Accelerate Translational and Clinical Cancer Research
Introducing the most comprehensive commercially available NGS assay for detecting gene fusions in cancer using an automated nanoscale library prep workflow SOUTH SAN FRANCISCO, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider
View HTML
Toggle Summary Fluidigm Introduces Automated Advanta Solid Tumor NGS Library Prep Assay Using Microfluidics Technology
The first commercially available targeted NGS assay that enables simultaneous detection of somatic variants across 53 solid tumor genes using a highly efficient microfluidic library prep workflow SOUTH SAN FRANCISCO, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an
View HTML
Toggle Summary Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , May 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of May 7, 2019 , under Fluidigm’s 2017
View HTML
Toggle Summary Fluidigm to Participate in Upcoming Health Care Investor Conferences
SOUTH SAN FRANCISCO, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor
View HTML
Toggle Summary Fluidigm Announces First Quarter 2019 Financial Results
First quarter revenue increased 19 percent to $30.1 million Mass cytometry revenue growth of 110 percent in first quarter Strong mass cytometry and Imaging Mass Cytometry instrument adoption First complete sample-to-answer solution for deep immune profiling in mass cytometry SOUTH SAN FRANCISCO,
View HTML
Toggle Summary Leading Cancer Center in Japan Selects Hyperion Imaging System to Expand Immuno-Oncology Research Studies in Colorectal Cancer
SOUTH SAN FRANCISCO, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (NASDAQ:FLDM) announced today that the Group for Innovative Cancer Treatment Division of the National Cancer Center in Japan has expanded its clinical research in colorectal cancer using the Hyperion™ Imaging
View HTML
Toggle Summary Fluidigm Announces 8th Annual Mass Cytometry Summit
Fluidigm invites researchers to the world’s largest global mass cytometry conference in Vancouver, Canada SOUTH SAN FRANCISCO, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif. , April 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report first quarter 2019 financial results on Thursday,
View HTML
Toggle Summary Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research (AACR) Meeting
A comprehensive suite of multi-omic cancer research solutions for deep profiling of the tumor microenvironment and immune response SOUTH SAN FRANCISCO, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve
View HTML